Complete Guide to Fat Loss Without GLP-1 (works 90% of the time)

DeLauer frames this as the single most important dietary change when coming off GLP-1 drugs. He challenges the practice of merely tapering the medication, which he says just enables a slow return to old eating patterns. Instead, he wants to create a deliberate metabolic jolt. By going very low-carb, the returning appetite is steered toward protein and fat, which are inherently anabolic and support the hormonal and structural rebuilding that should accompany the calorie increase. He cites a Nutrition & Metabolism study on short-term keto stimulating the adrenergic system and an AJCN trial where a 30–40% protein keto diet led to spontaneous calorie reduction and better macronutrient ratios. He sees this not as a lifelong keto prescription but as a 4–12 week bridge to metabolic self-sufficiency. He also notes that many critics say keto doesn’t work, but in this specific context of post-drug adaptation, he believes it is uniquely effective.

DeLauer is emphatic that the biggest mistake people make when they see the scale creep up is to double down on cardio. He explains that during GLP-1 use, people are essentially on 'life support' for muscle—they train only to maintain what they have in a catabolic environment. When the drug is stopped, the influx of calories provides the first real chance to build muscle. He wants viewers to shift their mindset: instead of fearing the scale, they should use the extra energy to fuel high-quality training. The prescription is specific: 30–60 second bursts of all-out effort, not long, slow drudgery. He even allows that Zone 2 can come later, but intensity must be prioritized first because it aligns with the body's ability to flux energy at a high rate. This, combined with the low-carb protocol, creates a synergistic effect for metabolic health.

DeLauer notes that even when someone increases their calorie intake from a very low level (e.g., 1,000 kcal) to 2,000 kcal, they are unlikely to proportionally increase their micronutrient intake; hunger often leads to junk food. Therefore, he recommends a simple, low-effort solution: a good multivitamin. For those open to it, he suggests beef liver or liver capsules as natural nutrient-dense alternatives. He doesn't endorse a specific brand, framing this as a straightforward, accessible step that can prevent the subtle deficiencies that might undermine the transition.

DeLauer stresses that this is not a ‘thyroid hack’ to boost metabolism but a way to equip the gland with the raw materials it needs to function flexibly. He connects this to the overall three-pronged approach: increasing calories, increasing activity, and increasing positive hormone flux. He wants the thyroid to naturally rise in step with the other changes. He suggests seaweed or kelp for iodine and Brazil nuts for selenium as whole-food options that are easy to add. This recommendation fits within the broader post-drug protocol and is meant to prevent the common complaint of feeling cold, fatigued, or sluggish after stopping the medication.

DeLauer argues that the period immediately post-drug is a metabolic turning point. He cites a Nutrition & Metabolism study demonstrating that even short-term ketogenic or low-carb eating stimulates adrenergic activity, which acts as a shock to the body and directly preserves muscle while inhibiting breakdown. His logic: when appetite returns, forcing oneself into a very low-carb pattern means the only remaining options are protein and fat, which are inherently muscle-sparing and improve metabolic flexibility. He contrasts this with the common practice of simply titrating the drug dose down, calling that a slow return to old habits. Instead, he wants to create a deliberate metabolic shift. He also references an American Journal of Clinical Nutrition trial where a high-protein keto group (30–40% protein) ate 160–200 fewer calories spontaneously compared to a moderate-carb group, while maintaining a better protein:fat ratio, reinforcing the appetite-suppressing and muscle-preserving effects of low-carb in this context.

DeLauer explains that while on the drug, people are on 'life support' with their resistance training—simply doing enough to preserve muscle in a catabolic state. The moment the drug is stopped and food intake rises, the body has the energy and raw materials to actually build tissue. He urges viewers to capitalize on this by ramping up intensity in the gym. He explicitly says that the increased appetite should be directed toward muscle-building activity rather than being fought with more cardio, which would only deepen the metabolic slowdown. This shift in mindset—from maintenance to construction—is central to his strategy for long-term success without the drug.

DeLauer points out that GLP-1 use creates a 'low energy flux' state: low calorie intake and low activity due to diminished energy. When calories increase post-drug, the instinct to burn them off with cardio puts the body in an even more depleted condition. Instead, he prescribes high-intensity intervals—30-second to 1-minute sprints on a bike, treadmill, or elliptical—paired with resistance training. This approach, he says, creates a 'high energy flux' that stimulates mitochondrial function and muscle retention while allowing the body to use the incoming nutrients productively. He emphasizes that Zone 2 cardio can be reintroduced later, but initially, intensity is key to capitalizing on the metabolic window.

DeLauer clarifies that this is not about 'boosting' metabolism but about giving the thyroid the raw materials it needs to fluctuate appropriately. Iodine is a precursor for both T3 and T4, while selenium is required for the conversion of T4 into active T3. He recommends seaweed, kelp, or an iodine supplement, and Brazil nuts for selenium. He ties this into the overall three-pronged approach of increasing calories, activity, and hormone flux in unison. Without these nutrients, the thyroid may struggle to upregulate, leading to fatigue and fat regain. This is a simple, food-first strategy that he positions as essential but overlooked.